Product Description
Cefoperazone is a semisynthetic, broad-spectrum, third-generation cephalosporin with antibacterial activity. Cefoperazone binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. I (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cefoperazone)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Austria | Bangladesh | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Egypt | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Korea | Latvia | Lithuania | Malaysia | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Sri Lanka | Taiwan | Thailand | Turkey | Ukraine | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Respiratory Tract Infections|Urinary Tract Infections
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CTR20221980 | P1 |
Completed |
Healthy Volunteers |
2023-05-22 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
| CTR20130998 | P2 |
Recruiting |
Respiratory Tract Infections|Urinary Tract Infections |
None |
2025-04-29 |
Patient Enrollment|Treatments |